Guided by hope.

2011–2012 ANNUAL REPORT
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>To Our Komen Family</td>
<td>1</td>
</tr>
<tr>
<td>Research</td>
<td>2</td>
</tr>
<tr>
<td>Community Health</td>
<td>3</td>
</tr>
<tr>
<td>Advocacy</td>
<td>4</td>
</tr>
<tr>
<td>Global Outreach</td>
<td>5</td>
</tr>
<tr>
<td>Komen Affiliates</td>
<td>6</td>
</tr>
<tr>
<td>Financials</td>
<td>7</td>
</tr>
<tr>
<td>Our Sincerest Appreciation</td>
<td>8</td>
</tr>
<tr>
<td>Scientific Advisory Board &amp; Komen Scholars</td>
<td>9</td>
</tr>
</tbody>
</table>

### 2012 Board of Directors

- **Dr. LaSalle Leffall, Jr., Chairperson**
- Jane Abraham
- Ambassador Nancy G. Brinker
- Eric Brinker
- Elyse Gellerman

- Brenda Lauderback
- Linda Law
- Connie O’Neill
- John D. Raffaelli
Susan G. Komen’s most recent fiscal year was one of great accomplishment and great challenge.

• In fiscal year 2012, we devoted $58 million to more than 100 research grants aimed at curing, and hopefully preventing, breast cancer.

• We funded thousands of community health programs providing basic medical and social support for the neediest of our society.

• We advocated for cancer care access and research at the federal level and in the states.

• And we helped establish new global programs, including the landmark Pink Ribbon Red Ribbon initiative, through unique partnerships that we were proud to forge.

Our total investment in breast cancer research over our three decades topped $610 million in FY 2012, the largest amount by a non-profit organization along the entire continuum of cancer care. In our communities, we reached millions of women through education programs; paid for more than 600,000 breast screenings for low-income women, and helped pay the costs of medical treatment, living expenses, and programs for social and emotional support for another 100,000 low-income and uninsured women and men. Our total investment in community health programs neared $1.5 billion in FY 2012.

While we experienced a year of great achievement, we also faced challenge. We know Komen supporters give us more than money and time. They give us their trust, and we take it very seriously. The grant-making decision we made for Planned Parenthood in FY 2012, which we subsequently corrected, created great controversy; we take full accountability for what resulted. We never took our eye off the ball when it came to our mission. We learned from what we did right and from what we did wrong. And, we pressed on to work for the millions of women and men who rely on us, ensuring there was no interruption or gap in services for those who need our support the most.

We have never wavered from our mission to fund the best research, the most meaningful public policy and community health programs, and to build our work globally.

As always, I’m so grateful for those who have been on this journey to fulfill my promise to my sister Suzy, and to all women and men, to end this disease forever.

None of our work would be possible without our friends and donors. Thank you, as always, for your continued support.

Nancy G. Brinker
Founder
Guided by hope. Research

Komen’s Scientific Advisory Board and the Komen Scholars – a team of 74 top-level scientists and advocates – helped guide and prioritize our global research investment.

We made research investments in projects that explore extreme challenges in breast cancer, such as understanding the genetic makeup of breast cancer, identifying breast cancer at the earliest stages, developing targeted therapies for triple-negative cancer and overcoming disparities in outcomes.

In FY 2012 Komen invested $58M toward research projects

We invested $8 million in large-scale team science projects called Promise Grants to understand and overcome breast cancer that recurs more than five years after the initial diagnosis.

We continued our quest to understand why women of color and underserved women are diagnosed with more aggressive breast cancer and have poorer outcomes — and how to overcome these disparities. To that end, we have supported a total of 242 research grants focused on these disparities through FY 2012, including a grant to Komen Scholar, Olufunmilayo Olopade, who is identifying the genetic mutations that make women of African ancestry more likely to develop breast cancer at an early age.

More than 90 clinical trials were supported in FY 2012, including a trial that will help determine whether a multi-gene tumor assay (Oncotype DX®) can be used to identify women with node-positive breast cancer who could forego chemotherapy.

Also this fiscal year, we continued our longstanding partnership with the American Society of Clinical Oncology with a $1 million investment to support the development of CancerLinQ. This “rapid learning system” will drive advances in evidence-based clinical medicine and provide real-time, personalized guidance and quality feedback to physicians.
Together with our Affiliates, we distributed $93 million in grants to more than 1,900 nonprofit organizations. Hundreds of thousands of low-income, uninsured and medically underserved women throughout the country were provided support by these funds in four key areas of need:

- Education and awareness
- Free or reduced cost screenings
- Assistance for treatment
- Financial and social support

SERVING WOMEN IN RURAL AREAS

Women living in rural areas face many barriers to the detection and treatment of breast cancer, including long distances to screening facilities. The Wyoming Women First Program, a collaboration among GE, the State of Wyoming and Komen, brought innovative approaches to better serve millions of women living in rural Wyoming.

Together, we connected with in-state partners to increase promotion and awareness of Wyoming Women First.

GE deployed a new mobile mammography van to travel across Wyoming to increase access to breast cancer screening, along with funding to nonprofit organizations that provide education, patient navigation and breast health vouchers to underserved women.

OUTREACH TO HISPANIC WOMEN

A pilot partnership with four Mexican Consulates in the U.S. launched a new health program designed to address breast cancer screening and awareness among Mexican, Mexican-American and Hispanic women in the U.S.

Breast cancer is the leading cause of cancer-related deaths in Hispanic women. Differences in access to care and treatment likely contribute to the disparity.

We actively worked to address the barriers to care that are unique to Hispanic and Latina populations, guiding women in education, outreach and patient navigation programs in collaboration with Mexican Consulate offices and Komen Affiliates.

ESTABLISHING A HEALTHCARE COALITION

Komen provided various grants to the Primary Care Coalition (PCC) of Montgomery County, Maryland to ensure women received less fragmented healthcare for breast cancer. The grant-funded program was then implemented in various healthcare facilities in Prince George’s County, Washington, D.C., and Northern Virginia. The Primary Care Coalition reported:

- All sites increased mammogram screening rates.
- Another site worked closely with one mammography provider to decrease the no-show rate for appointments from 26% to 6%.
- Decreased average cycle time from referral to screening from 100 days to 30 days.
- Increased mammogram capacity by 30%.

More than 100,000 Komen volunteers across the nation helped bring essential programs to those who need it most.
The Komen Advocacy Alliance developed and implemented various education and advocacy initiatives to encourage elected and agency officials to support policies and legislation that further the overall mission to end breast cancer forever.

We focused on advocating for policies that directly serve individuals with breast cancer, survivors of breast cancer and those who may develop breast cancer in the future. Such policies provide access to and coverage for quality preventive programs and quality treatment for women and men facing breast cancer.

The Alliance also advocated for continued state and federal funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Due in part to our efforts, the NBCCEDP program preserved more than $85 million in state and more than $200 million in federal funding for safety-net breast cancer screening programs that serve low income, uninsured and underinsured women.

In FY 2012, we continued to cultivate key relationships on Capitol Hill by hosting our annual Susan G. Komen Lobby Day. The event included more than 200 advocates who took part in trainings and nearly 400 congressional meetings.
The GE Foundation awarded our organization a $5.5 million gift, the largest ever received from a single foundation. Portions of the gift established and further developed comprehensive awareness and education campaigns and breast health screening in Saudi Arabia and increased community-led breast cancer screenings in the People’s Republic of China.

As part of our global outreach, we took the mission to 16 different locations in 10 different countries where hopeful supporters walked, ran and advocated for breast cancer programs through our signature Race for the Cure Series. More than $1.5M in net proceeds was reinvested into the local communities for educational programming, awareness campaigns, no-cost screening programs and survivor support.

Together, Susan G. Komen®, the George W. Bush Institute, the U.S. Department of State, the U.S. President’s Emergency Plan for AIDS Relief, and the Joint United Nations Programme on HIV/AIDS announced the launch of Pink Ribbon Red Ribbon. This innovative partnership leverages public and private investment in global health to combat cervical and breast cancer — two of the leading causes of cancer death in women — in Sub-Saharan Africa and Latin America. Pink Ribbon Red Ribbon expands the availability of vital cervical cancer screening and treatment and breast care education — especially for women in developing nations most at risk of getting cervical cancer because they are HIV-positive. This public and private initiative includes an initial $3.3 million commitment to Komen from Merck, one of the founding corporate participants, for use in executing and implementing this initiative.

In FY 2012, Komen’s Global Programming invested more than $2.5M in international community health grants in over 23 countries.
Thanks to survivors, volunteers and activists dedicated to the fight against breast cancer, the Komen Affiliate Network is the nation’s largest private funder of community-based breast health education and breast cancer screening and treatment programs.
CONSOLIDATED STATEMENT OF ACTIVITIES

Fiscal Year Ended March 31

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public Support and Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$179,492</td>
<td>$163,857</td>
</tr>
<tr>
<td>Komen Race for the Cure and 3 Day</td>
<td>271,386</td>
<td>257,850</td>
</tr>
<tr>
<td>Other Revenue</td>
<td>20,872</td>
<td>7,190</td>
</tr>
<tr>
<td><strong>Total Gross Revenue</strong></td>
<td>$471,750</td>
<td>$428,897</td>
</tr>
<tr>
<td>Less Direct Benefits to Donors and Sponsors</td>
<td>(32,784)</td>
<td>(29,932)</td>
</tr>
<tr>
<td><strong>Net Public Support and Revenue</strong></td>
<td>$438,966</td>
<td>$398,965</td>
</tr>
<tr>
<td><strong>Program Services Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>75,302</td>
<td>69,146</td>
</tr>
<tr>
<td>Education</td>
<td>181,092</td>
<td>173,813</td>
</tr>
<tr>
<td>Screening</td>
<td>54,089</td>
<td>50,338</td>
</tr>
<tr>
<td>Treatment</td>
<td>23,252</td>
<td>24,985</td>
</tr>
<tr>
<td><strong>Total Program Services Expenses</strong></td>
<td>$333,735</td>
<td>$318,282</td>
</tr>
<tr>
<td><strong>Supporting Services Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Administration</td>
<td>27,253</td>
<td>23,064</td>
</tr>
<tr>
<td>Fundraising Costs</td>
<td>47,990</td>
<td>52,119</td>
</tr>
<tr>
<td><strong>Total Supporting Services Expenses</strong></td>
<td>$75,243</td>
<td>$75,183</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$408,978</td>
<td>$393,465</td>
</tr>
<tr>
<td>Change in Net Assets</td>
<td>29,988</td>
<td>5,500</td>
</tr>
<tr>
<td><strong>Net Assets at the Beginning of the Year</strong></td>
<td>$163,231</td>
<td>$193,219</td>
</tr>
<tr>
<td><strong>Net Assets at the End of the Year</strong></td>
<td>$193,219</td>
<td>$198,719</td>
</tr>
</tbody>
</table>

The Consolidated Statements of Financial Position and Activities as reported above have been audited by Ernst & Young, LLP in accordance with auditing standards generally accepted in the United States. To review our complete audited financial statements and the Form 990s filed with the IRS, please visit www.komen.org.
Our Sincerest Appreciation

In FY 2012, sponsors, partners, donors and volunteers gave generously and enabled us to advance in research, community health, advocacy and global outreach. Thank you for your support, for the belief and commitment that you have in saving lives and ending breast cancer forever.

The Komen Million Dollar Council Elite is a special group of sponsors and partners who have committed to invest a financial contribution of $1 million annually in the fight to end breast cancer. Each of these organizations has found new and innovative ways to raise awareness about breast cancer and encourage people from all walks of life to get involved in finding the cures. We thank them for their generous support.

**MILLION DOLLAR COUNCIL ELITE:**
- American Airlines®
- Bank of America®
- Belk®
- Caterpillar Foundation®
- Condé Nast Publications – Rally for the Cure®
- Ford®
- GE
- General Mills®
- Merck
- New Balance Athletic Shoe, Inc.®
- Yoplait®

Komen’s Million Dollar Council is a special group of sponsors, partners and corporate foundations who have contributed a minimum of $1 million in support of our promise to save lives and end breast cancer forever. These companies and brands have found unique ways to engage their consumers, associates and civic programs in the fight against breast cancer, raising valuable funds and awareness for our cause. We thank them for their generous support.

**MILLION DOLLAR COUNCIL:**
- ACH Food Companies, Inc.
- Acushnet Company
- Ask.com
- Carlisle®
- Dell™
- Deluxe®
- Energizer®
- Fuze®
- Georgia Pacific
- Hallmark®
- Holland America Line®
- KitchenAid®
- Lowe’s®
- Maingate
- Major League Baseball®
- Meredith Corporation®
- Mohawk Group
- On the Border®
- Oreck®
- Pandora®
- Payless Shoe Source®
- Princess Cruises Community Foundation™
- RE/MAX®
- Triple Negative Breast Cancer Foundation®
- Tubbs Romp to Stomp™
- United States Bowling Congress – Bowl for the Cure®
- Wacoal®
- Zeta Tau Alpha
- Zumba Fitness
FY 2012 Scientific Advisory Board & Komen Scholars

Komen's Scientific Advisory Board (SAB) provides strategic guidance and direction for the Komen organization, in particular, the research and scientific programs, and has played a key role in guiding and prioritizing Komen's global research investment. The SAB also serves as the Executive Committee for the Komen Scholars.

Komen Scholars is an advisory group of 68 distinguished scholars and leaders in breast cancer research and advocacy who have made significant contributions to advancing the field, or who demonstrate significant promise of leading the field with important advances in the future, and are committed to furthering Komen's mission.

**SCIENTIFIC ADVISORY BOARD (EXECUTIVE COMMITTEE)**

Eric P. Winer, M.D., Chief Scientific Advisor
Dana-Farber Cancer Institute

Myles Brown, M.D.
Dana-Farber Cancer Institute

Powel Brown, M.D., Ph.D.
University of Texas MD Anderson Cancer Center

Amelie G. Ramirez, Dr.PH
University of Texas Health Science Center at San Antonio

George W. Sledge, M.D.
Melvin and Bren Simon Cancer Center Indiana University School of Medicine

Chris Tannous, Ph.D.
Komen Advocate in Science, Fountain Valley, CA

**KOMEN SCHOLARS**

Benjamin Anderson, M.D.
Fred Hutchinson Cancer Research Center

Carlos Arteaga, M.D.
Vanderbilt-Ingram Cancer Center

Alan Ashworth, Ph.D., FRS
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research

Suiln Badve, M.D., FRCPath
Indiana University Simon Cancer Center

José Baselga, M.D., Ph.D.
Massachusetts General Hospital Cancer Center

Kimberly Blackwell, M.D.
Duke University School of Medicine

Gerard Blobel, M.D., Ph.D.
Duke University School of Medicine

Melissa Bondy, Ph.D.
Baylor College of Medicine

Angela Brodie, Ph.D.
University of Maryland School of Medicine

Lisa Carey, M.D.
UNC Lineberger Comprehensive Cancer Center

Giuseppe Curigliano, M.D., Ph.D.
European Institute of Oncology

Claire Dees, M.D., Ms.C.
UNC Lineberger Comprehensive Cancer Center

Angelo Di Leo, M.D., Ph.D.
Hospital of Prito, Istituto Toscano Tumori

Susan Domchek, M.D.
Abramson Cancer Center at the University of Pennsylvania

Mary Elliott
Komen Advocate in Science

Carol Fabian, M.D.
University of Kansas Medical Center

Sandra Fineestone, PsyD.
Komen Advocate in Science

Silvia Formenti, M.D.
New York University School of Medicine and Langone Medical Center

William Foulkes, M.B., Ph.D.
McGill University

Patricia Ganz, M.D.
University of California, Los Angeles

Judy Garber, M.D., MPH
Dana-Farber Cancer Institute

Karen Gelmon, M.D., FRCP
University of British Columbia and BC Cancer Agency

Ana Gonzalez-Angulo, M.D., M.Sc., FACP
University of Texas MD Anderson Cancer Center

Julie Gralow, M.D.
University of Washington School of Medicine and Seattle Cancer Care Alliance

Joe Gray, Ph.D.
Knight Cancer Institute at Oregon Health & Science University

Theresa Guise, M.D.
Indiana University School of Medicine

Susan Hankinson, Sc.D.
Brigham and Women’s Hospital and Harvard Medical School

Daniel Hayes, M.D.
University of Michigan Health System

Mien-Chie Hung, Ph.D.
University of Texas MD Anderson Cancer Center

Nola Hylton, Ph.D.
University of California, San Francisco

Nancy Hynes, Ph.D.
Friedrich Miescher Institute for Biomedical Research

Cheryl Jennigan
Komen Advocate in Science

Virgil (Craig) Jordan, OBE, Ph.D., DSc.
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

Bella Kaufman, M.D.
Chaim Sheba Medical Centre

Mary-Claire King, Ph.D.
University of Washington School of Medicine

Ian Krop, M.D., Ph.D.
Dana-Farber Cancer Institute

Adrian Lee, Ph.D.
University of Pittsburgh Cancer Institute

David Livingston, M.D.
Dana-Farber Cancer Institute

H. Kim Lyerly, M.D.
Duke University School of Medicine

Eleftherios Mamounas, M.D., MPH
Allman Cancer Center and Northeastern Ohio Universities College of Medicine

Anne McTiernan, M.D., Ph.D.
Fred Hutchinson Cancer Research Center

Funda Meric-Bernstam, M.D.
University of Texas MD Anderson Cancer Center

Kathy Miller, M.D.
Indiana University Simon Cancer Center

Gordon Mills, M.D., Ph.D.
University of Texas MD Anderson Cancer Center

Harikrishna Nakshatri, B.V.Sc. (DVM), Ph.D.
Indiana University School of Medicine

Olufunmilayo Olopade, M.D., FACP
University of Chicago Medical Center

Bert O’Malley, M.D.
Baylor College of Medicine

Ramon Parsons, M.D., Ph.D.
Columbia University Medical Center

Ann Partridge, M.D., MPH
Dana-Farber Cancer Institute

Vered Stearns, M.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Sara Sukumar, Ph.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

William Symmans, M.D.
University of Texas MD Anderson Cancer Center

Thea Tlsty, Ph.D.
University of California, San Francisco

Geoffrey Wahl, Ph.D.
The Salk Institute for Biological Studies

Danny Welch, Ph.D.
The Kansas University Medical Center

Julia White, M.D.
Stephanie Spielman Comprehensive Breast Center, The Ohio State University Medical School

Antonio Wolff, M.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Douglas Yee, M.D.
Masonic Cancer Center, University of Minnesota